Inhibikase Therapeutics, Inc. (IKT) Stock Score, Valuation & Financial Research

Inhibikase Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IKT

Inhibikase Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.06. These figures are a research snapshot, not a buy or sell recommendation.

What Inhibikase Therapeutics, Inc. does

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Inhibikase Therapeutics is a clinical-stage pharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of protein kinase inhibitor therapeutics to treat cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension, relying on capital raises and financing to fund its clinical trial programs.

Products and services

  • The company is developing IKT-001, a small molecule therapeutic candidate designed to modify the course of Pulmonary Arterial Hypertension (PAH) by targeting specific kinase pathways.

Brands and product families

  • IKT-001 — Lead clinical-stage product candidate for the treatment of Pulmonary Arterial Hypertension. Source

Suppliers, materials and equipment

  • Clinical trial supply organization — An unnamed organization providing clinical trial supply services; the supplier company is unnamed. Source

Business relationships and partnerships

  • Contract Research Organization (CRO) — The company has a contractual arrangement with a CRO to support its Phase 2b and subsequent Phase 3 clinical studies for IKT-001, with total contracted amounts reaching $73.7 million as of March 2026. Source

Competitors and product-market comparisons

  • Companies developing imatinib-based therapies — The company notes that other entities have investigated imatinib delivered by inhalation for PAH, which failed to demonstrate statistically significant therapeutic effects. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting underserved cardiopulmonary diseases Source
  • FDA engagement supporting transition to pivotal Phase 3 study Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Significant clinical trial costs and reliance on third-party CRO performance Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IKT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.06
Market capitalization:
271.33M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -60.64M
Free cash flow:
USD -27.8M
Cash:
USD 31.21M
Total debt:
USD 0.00
EPS:
USD -0.48

What stands out

  • Free cash flow is USD -27.8M, negative for the stored period.
  • The balance sheet shows USD 31.21M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 31.21M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IKT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can IKT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IKT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IKT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IKT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research IKT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.